Subscribe
Denise Guerrero, nuclear medicine technician, prepares a vile of lutetium Lu 177 vipivotide tetraxetan for a patient infusion treatment at Brooke Army Medical Center, Joint Base San Antonio – Fort Sam Houston, Texas, Feb. 27, 2025. Lutetium Lu 177 vipivotide tetraxetan, known by the brand name Pluvicto®, is a radioactive compound that targets prostate-specific membrane antigen (PSMA), a protein found on prostate cancer cells. (DoD photo by Jason W. Edwards)
| Date Taken: | 02.27.2025 |
| Date Posted: | 03.11.2025 11:44 |
| Photo ID: | 8908429 |
| VIRIN: | 250227-D-HZ730-1467 |
| Resolution: | 3233x4850 |
| Size: | 2.84 MB |
| Location: | JOINT BASE SAN ANTONIO, TEXAS, US |
| Web Views: | 24 |
| Downloads: | 2 |
This work, Nuclear Medicine theranostic treatment [Image 2 of 2], by Jason W. Edwards, identified by DVIDS, must comply with the restrictions shown on https://www.dvidshub.net/about/copyright.
No keywords found.
